nodes	percent_of_prediction	percent_of_DWPC	metapath
Indinavir—CYP3A4—bone cancer	0.347	1	CbGaD
Indinavir—ABCC1—Epirubicin—bone cancer	0.0876	0.172	CbGbCtD
Indinavir—ABCC2—Carboplatin—bone cancer	0.0602	0.118	CbGbCtD
Indinavir—ABCC2—Cisplatin—bone cancer	0.0514	0.101	CbGbCtD
Indinavir—ABCC1—Doxorubicin—bone cancer	0.0465	0.0912	CbGbCtD
Indinavir—ABCC1—Methotrexate—bone cancer	0.0451	0.0884	CbGbCtD
Indinavir—SLCO1A2—Methotrexate—bone cancer	0.0403	0.0789	CbGbCtD
Indinavir—SLCO1B1—Methotrexate—bone cancer	0.038	0.0744	CbGbCtD
Indinavir—ABCC2—Doxorubicin—bone cancer	0.0345	0.0675	CbGbCtD
Indinavir—ABCC2—Methotrexate—bone cancer	0.0334	0.0654	CbGbCtD
Indinavir—CYP2C9—Cisplatin—bone cancer	0.0173	0.0338	CbGbCtD
Indinavir—ABCB1—Cisplatin—bone cancer	0.0168	0.0328	CbGbCtD
Indinavir—ABCB1—Doxorubicin—bone cancer	0.0112	0.022	CbGbCtD
Indinavir—ABCB1—Methotrexate—bone cancer	0.0109	0.0213	CbGbCtD
Indinavir—CYP2D6—Doxorubicin—bone cancer	0.0106	0.0207	CbGbCtD
Indinavir—CYP3A4—Doxorubicin—bone cancer	0.00673	0.0132	CbGbCtD
Indinavir—ABCC2—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00135	0.0377	CbGpPWpGaD
Indinavir—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00127	0.0354	CbGpPWpGaD
Indinavir—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00126	0.0353	CbGpPWpGaD
Indinavir—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00119	0.0332	CbGpPWpGaD
Indinavir—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00116	0.0324	CbGpPWpGaD
Indinavir—Lopinavir—CYP3A4—bone cancer	0.00103	0.39	CrCbGaD
Indinavir—Nelfinavir—CYP3A4—bone cancer	0.000953	0.362	CrCbGaD
Indinavir—ABCC2—Irinotecan Pathway—CYP3A4—bone cancer	0.000862	0.0241	CbGpPWpGaD
Indinavir—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.000852	0.0238	CbGpPWpGaD
Indinavir—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000836	0.0234	CbGpPWpGaD
Indinavir—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.000809	0.0226	CbGpPWpGaD
Indinavir—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000738	0.0206	CbGpPWpGaD
Indinavir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000725	0.0203	CbGpPWpGaD
Indinavir—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000693	0.0194	CbGpPWpGaD
Indinavir—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000679	0.019	CbGpPWpGaD
Indinavir—Saquinavir—CYP3A4—bone cancer	0.000653	0.248	CrCbGaD
Indinavir—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000647	0.0181	CbGpPWpGaD
Indinavir—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000634	0.0177	CbGpPWpGaD
Indinavir—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000597	0.0167	CbGpPWpGaD
Indinavir—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000595	0.0166	CbGpPWpGaD
Indinavir—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000594	0.0166	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000593	0.0166	CbGpPWpGaD
Indinavir—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00059	0.0165	CbGpPWpGaD
Indinavir—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000564	0.0158	CbGpPWpGaD
Indinavir—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000558	0.0156	CbGpPWpGaD
Indinavir—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000537	0.015	CbGpPWpGaD
Indinavir—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000498	0.0139	CbGpPWpGaD
Indinavir—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000445	0.0124	CbGpPWpGaD
Indinavir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000424	0.0119	CbGpPWpGaD
Indinavir—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000421	0.0118	CbGpPWpGaD
Indinavir—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000404	0.0113	CbGpPWpGaD
Indinavir—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000389	0.0109	CbGpPWpGaD
Indinavir—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000388	0.0109	CbGpPWpGaD
Indinavir—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000366	0.0102	CbGpPWpGaD
Indinavir—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.00036	0.0101	CbGpPWpGaD
Indinavir—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000347	0.00971	CbGpPWpGaD
Indinavir—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000343	0.0096	CbGpPWpGaD
Indinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000341	0.00954	CbGpPWpGaD
Indinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000319	0.00891	CbGpPWpGaD
Indinavir—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000312	0.00873	CbGpPWpGaD
Indinavir—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.0003	0.0084	CbGpPWpGaD
Indinavir—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000296	0.00827	CbGpPWpGaD
Indinavir—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000287	0.00803	CbGpPWpGaD
Indinavir—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000285	0.00796	CbGpPWpGaD
Indinavir—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000278	0.00779	CbGpPWpGaD
Indinavir—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000277	0.00776	CbGpPWpGaD
Indinavir—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000276	0.00772	CbGpPWpGaD
Indinavir—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000274	0.00766	CbGpPWpGaD
Indinavir—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000256	0.00716	CbGpPWpGaD
Indinavir—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000254	0.0071	CbGpPWpGaD
Indinavir—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000233	0.00652	CbGpPWpGaD
Indinavir—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000232	0.00649	CbGpPWpGaD
Indinavir—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000229	0.0064	CbGpPWpGaD
Indinavir—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000214	0.006	CbGpPWpGaD
Indinavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00021	0.00588	CbGpPWpGaD
Indinavir—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000209	0.00585	CbGpPWpGaD
Indinavir—Pneumonia—Methotrexate—bone cancer	0.000202	0.00194	CcSEcCtD
Indinavir—Gastrointestinal disorder—Cisplatin—bone cancer	0.000202	0.00194	CcSEcCtD
Indinavir—Gastritis—Doxorubicin—bone cancer	0.0002	0.00192	CcSEcCtD
Indinavir—Pain—Cisplatin—bone cancer	0.0002	0.00192	CcSEcCtD
Indinavir—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000199	0.00192	CcSEcCtD
Indinavir—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000199	0.00191	CcSEcCtD
Indinavir—Muscular weakness—Doxorubicin—bone cancer	0.000199	0.00191	CcSEcCtD
Indinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000199	0.00557	CbGpPWpGaD
Indinavir—Renal failure—Methotrexate—bone cancer	0.000198	0.0019	CcSEcCtD
Indinavir—Dysuria—Epirubicin—bone cancer	0.000197	0.0019	CcSEcCtD
Indinavir—Abdominal distension—Doxorubicin—bone cancer	0.000197	0.00189	CcSEcCtD
Indinavir—Upper respiratory tract infection—Epirubicin—bone cancer	0.000196	0.00188	CcSEcCtD
Indinavir—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000195	0.00547	CbGpPWpGaD
Indinavir—Pollakiuria—Epirubicin—bone cancer	0.000195	0.00187	CcSEcCtD
Indinavir—Sweating—Methotrexate—bone cancer	0.000193	0.00185	CcSEcCtD
Indinavir—Feeling abnormal—Cisplatin—bone cancer	0.000193	0.00185	CcSEcCtD
Indinavir—Weight increased—Epirubicin—bone cancer	0.000192	0.00185	CcSEcCtD
Indinavir—Haematuria—Methotrexate—bone cancer	0.000192	0.00184	CcSEcCtD
Indinavir—Pancreatitis—Doxorubicin—bone cancer	0.000192	0.00184	CcSEcCtD
Indinavir—Hyperglycaemia—Epirubicin—bone cancer	0.000191	0.00183	CcSEcCtD
Indinavir—Angina pectoris—Doxorubicin—bone cancer	0.00019	0.00183	CcSEcCtD
Indinavir—Hepatobiliary disease—Methotrexate—bone cancer	0.00019	0.00183	CcSEcCtD
Indinavir—Pneumonia—Epirubicin—bone cancer	0.000189	0.00182	CcSEcCtD
Indinavir—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00526	CbGpPWpGaD
Indinavir—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000187	0.00179	CcSEcCtD
Indinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000186	0.00521	CbGpPWpGaD
Indinavir—Renal failure—Epirubicin—bone cancer	0.000185	0.00178	CcSEcCtD
Indinavir—Body temperature increased—Cisplatin—bone cancer	0.000185	0.00177	CcSEcCtD
Indinavir—Neuropathy peripheral—Epirubicin—bone cancer	0.000185	0.00177	CcSEcCtD
Indinavir—Jaundice—Epirubicin—bone cancer	0.000184	0.00176	CcSEcCtD
Indinavir—Urinary tract infection—Epirubicin—bone cancer	0.000183	0.00176	CcSEcCtD
Indinavir—Dysuria—Doxorubicin—bone cancer	0.000183	0.00175	CcSEcCtD
Indinavir—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000182	0.00174	CcSEcCtD
Indinavir—Haemoglobin—Methotrexate—bone cancer	0.000182	0.00174	CcSEcCtD
Indinavir—Hepatitis—Methotrexate—bone cancer	0.000181	0.00173	CcSEcCtD
Indinavir—Haemorrhage—Methotrexate—bone cancer	0.000181	0.00173	CcSEcCtD
Indinavir—Sweating—Epirubicin—bone cancer	0.000181	0.00173	CcSEcCtD
Indinavir—Pollakiuria—Doxorubicin—bone cancer	0.000181	0.00173	CcSEcCtD
Indinavir—Haematuria—Epirubicin—bone cancer	0.00018	0.00172	CcSEcCtD
Indinavir—Pharyngitis—Methotrexate—bone cancer	0.000179	0.00172	CcSEcCtD
Indinavir—Urinary tract disorder—Methotrexate—bone cancer	0.000178	0.00171	CcSEcCtD
Indinavir—Hepatobiliary disease—Epirubicin—bone cancer	0.000178	0.00171	CcSEcCtD
Indinavir—Weight increased—Doxorubicin—bone cancer	0.000178	0.00171	CcSEcCtD
Indinavir—Urethral disorder—Methotrexate—bone cancer	0.000177	0.0017	CcSEcCtD
Indinavir—Sinusitis—Epirubicin—bone cancer	0.000177	0.0017	CcSEcCtD
Indinavir—Hyperglycaemia—Doxorubicin—bone cancer	0.000176	0.00169	CcSEcCtD
Indinavir—Pneumonia—Doxorubicin—bone cancer	0.000175	0.00168	CcSEcCtD
Indinavir—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000173	0.00166	CcSEcCtD
Indinavir—Hypersensitivity—Cisplatin—bone cancer	0.000172	0.00165	CcSEcCtD
Indinavir—Renal failure—Doxorubicin—bone cancer	0.000171	0.00164	CcSEcCtD
Indinavir—Erythema multiforme—Methotrexate—bone cancer	0.000171	0.00164	CcSEcCtD
Indinavir—Neuropathy peripheral—Doxorubicin—bone cancer	0.000171	0.00164	CcSEcCtD
Indinavir—Haemoglobin—Epirubicin—bone cancer	0.00017	0.00163	CcSEcCtD
Indinavir—Jaundice—Doxorubicin—bone cancer	0.00017	0.00163	CcSEcCtD
Indinavir—Urinary tract infection—Doxorubicin—bone cancer	0.000169	0.00163	CcSEcCtD
Indinavir—Hepatitis—Epirubicin—bone cancer	0.000169	0.00162	CcSEcCtD
Indinavir—Haemorrhage—Epirubicin—bone cancer	0.000169	0.00162	CcSEcCtD
Indinavir—Hypoaesthesia—Epirubicin—bone cancer	0.000168	0.00161	CcSEcCtD
Indinavir—Asthenia—Cisplatin—bone cancer	0.000168	0.00161	CcSEcCtD
Indinavir—Pharyngitis—Epirubicin—bone cancer	0.000168	0.00161	CcSEcCtD
Indinavir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000168	0.00469	CbGpPWpGaD
Indinavir—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000167	0.00468	CbGpPWpGaD
Indinavir—Sweating—Doxorubicin—bone cancer	0.000167	0.0016	CcSEcCtD
Indinavir—Urinary tract disorder—Epirubicin—bone cancer	0.000167	0.0016	CcSEcCtD
Indinavir—Haematuria—Doxorubicin—bone cancer	0.000166	0.00159	CcSEcCtD
Indinavir—Connective tissue disorder—Epirubicin—bone cancer	0.000166	0.00159	CcSEcCtD
Indinavir—Urethral disorder—Epirubicin—bone cancer	0.000166	0.00159	CcSEcCtD
Indinavir—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000165	0.00463	CbGpPWpGaD
Indinavir—Hepatobiliary disease—Doxorubicin—bone cancer	0.000165	0.00158	CcSEcCtD
Indinavir—Sinusitis—Doxorubicin—bone cancer	0.000163	0.00157	CcSEcCtD
Indinavir—Immune system disorder—Methotrexate—bone cancer	0.000163	0.00157	CcSEcCtD
Indinavir—Chills—Methotrexate—bone cancer	0.000162	0.00156	CcSEcCtD
Indinavir—Diarrhoea—Cisplatin—bone cancer	0.00016	0.00154	CcSEcCtD
Indinavir—Erythema multiforme—Epirubicin—bone cancer	0.00016	0.00153	CcSEcCtD
Indinavir—Alopecia—Methotrexate—bone cancer	0.00016	0.00153	CcSEcCtD
Indinavir—Malnutrition—Methotrexate—bone cancer	0.000157	0.00151	CcSEcCtD
Indinavir—Haemoglobin—Doxorubicin—bone cancer	0.000157	0.00151	CcSEcCtD
Indinavir—Flushing—Epirubicin—bone cancer	0.000157	0.00151	CcSEcCtD
Indinavir—Haemorrhage—Doxorubicin—bone cancer	0.000156	0.0015	CcSEcCtD
Indinavir—Hepatitis—Doxorubicin—bone cancer	0.000156	0.0015	CcSEcCtD
Indinavir—Hypoaesthesia—Doxorubicin—bone cancer	0.000156	0.00149	CcSEcCtD
Indinavir—Pharyngitis—Doxorubicin—bone cancer	0.000155	0.00149	CcSEcCtD
Indinavir—Urinary tract disorder—Doxorubicin—bone cancer	0.000154	0.00148	CcSEcCtD
Indinavir—Dysgeusia—Methotrexate—bone cancer	0.000154	0.00148	CcSEcCtD
Indinavir—Connective tissue disorder—Doxorubicin—bone cancer	0.000154	0.00148	CcSEcCtD
Indinavir—Urethral disorder—Doxorubicin—bone cancer	0.000153	0.00147	CcSEcCtD
Indinavir—Immune system disorder—Epirubicin—bone cancer	0.000153	0.00147	CcSEcCtD
Indinavir—Back pain—Methotrexate—bone cancer	0.000152	0.00146	CcSEcCtD
Indinavir—Chills—Epirubicin—bone cancer	0.000152	0.00146	CcSEcCtD
Indinavir—Alopecia—Epirubicin—bone cancer	0.000149	0.00143	CcSEcCtD
Indinavir—Vomiting—Cisplatin—bone cancer	0.000149	0.00143	CcSEcCtD
Indinavir—Vision blurred—Methotrexate—bone cancer	0.000148	0.00142	CcSEcCtD
Indinavir—Erythema multiforme—Doxorubicin—bone cancer	0.000148	0.00142	CcSEcCtD
Indinavir—Rash—Cisplatin—bone cancer	0.000147	0.00142	CcSEcCtD
Indinavir—Dermatitis—Cisplatin—bone cancer	0.000147	0.00141	CcSEcCtD
Indinavir—Malnutrition—Epirubicin—bone cancer	0.000147	0.00141	CcSEcCtD
Indinavir—Ill-defined disorder—Methotrexate—bone cancer	0.000146	0.0014	CcSEcCtD
Indinavir—Anaemia—Methotrexate—bone cancer	0.000145	0.0014	CcSEcCtD
Indinavir—Flushing—Doxorubicin—bone cancer	0.000145	0.00139	CcSEcCtD
Indinavir—Flatulence—Epirubicin—bone cancer	0.000145	0.00139	CcSEcCtD
Indinavir—Tension—Epirubicin—bone cancer	0.000144	0.00139	CcSEcCtD
Indinavir—Dysgeusia—Epirubicin—bone cancer	0.000144	0.00138	CcSEcCtD
Indinavir—Nervousness—Epirubicin—bone cancer	0.000143	0.00137	CcSEcCtD
Indinavir—Back pain—Epirubicin—bone cancer	0.000142	0.00137	CcSEcCtD
Indinavir—Malaise—Methotrexate—bone cancer	0.000142	0.00136	CcSEcCtD
Indinavir—Muscle spasms—Epirubicin—bone cancer	0.000141	0.00136	CcSEcCtD
Indinavir—Immune system disorder—Doxorubicin—bone cancer	0.000141	0.00136	CcSEcCtD
Indinavir—Vertigo—Methotrexate—bone cancer	0.000141	0.00136	CcSEcCtD
Indinavir—Chills—Doxorubicin—bone cancer	0.00014	0.00135	CcSEcCtD
Indinavir—Nausea—Cisplatin—bone cancer	0.000139	0.00133	CcSEcCtD
Indinavir—Vision blurred—Epirubicin—bone cancer	0.000139	0.00133	CcSEcCtD
Indinavir—Alopecia—Doxorubicin—bone cancer	0.000138	0.00133	CcSEcCtD
Indinavir—Cough—Methotrexate—bone cancer	0.000137	0.00132	CcSEcCtD
Indinavir—Ill-defined disorder—Epirubicin—bone cancer	0.000137	0.00131	CcSEcCtD
Indinavir—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000136	0.00381	CbGpPWpGaD
Indinavir—Malnutrition—Doxorubicin—bone cancer	0.000136	0.00131	CcSEcCtD
Indinavir—Anaemia—Epirubicin—bone cancer	0.000136	0.00131	CcSEcCtD
Indinavir—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000136	0.0038	CbGpPWpGaD
Indinavir—Agitation—Epirubicin—bone cancer	0.000135	0.0013	CcSEcCtD
Indinavir—Flatulence—Doxorubicin—bone cancer	0.000134	0.00129	CcSEcCtD
Indinavir—Arthralgia—Methotrexate—bone cancer	0.000134	0.00129	CcSEcCtD
Indinavir—Myalgia—Methotrexate—bone cancer	0.000134	0.00129	CcSEcCtD
Indinavir—Chest pain—Methotrexate—bone cancer	0.000134	0.00129	CcSEcCtD
Indinavir—Tension—Doxorubicin—bone cancer	0.000134	0.00128	CcSEcCtD
Indinavir—Dysgeusia—Doxorubicin—bone cancer	0.000133	0.00128	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000133	0.00128	CcSEcCtD
Indinavir—Malaise—Epirubicin—bone cancer	0.000133	0.00127	CcSEcCtD
Indinavir—Discomfort—Methotrexate—bone cancer	0.000132	0.00127	CcSEcCtD
Indinavir—Nervousness—Doxorubicin—bone cancer	0.000132	0.00127	CcSEcCtD
Indinavir—Vertigo—Epirubicin—bone cancer	0.000132	0.00127	CcSEcCtD
Indinavir—Syncope—Epirubicin—bone cancer	0.000132	0.00127	CcSEcCtD
Indinavir—Back pain—Doxorubicin—bone cancer	0.000132	0.00126	CcSEcCtD
Indinavir—Muscle spasms—Doxorubicin—bone cancer	0.000131	0.00126	CcSEcCtD
Indinavir—Palpitations—Epirubicin—bone cancer	0.00013	0.00125	CcSEcCtD
Indinavir—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00013	0.00363	CbGpPWpGaD
Indinavir—Loss of consciousness—Epirubicin—bone cancer	0.000129	0.00124	CcSEcCtD
Indinavir—Cough—Epirubicin—bone cancer	0.000128	0.00123	CcSEcCtD
Indinavir—Anaphylactic shock—Methotrexate—bone cancer	0.000128	0.00123	CcSEcCtD
Indinavir—Vision blurred—Doxorubicin—bone cancer	0.000128	0.00123	CcSEcCtD
Indinavir—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000128	0.00358	CbGpPWpGaD
Indinavir—Ill-defined disorder—Doxorubicin—bone cancer	0.000126	0.00121	CcSEcCtD
Indinavir—Nervous system disorder—Methotrexate—bone cancer	0.000126	0.00121	CcSEcCtD
Indinavir—Anaemia—Doxorubicin—bone cancer	0.000126	0.00121	CcSEcCtD
Indinavir—Thrombocytopenia—Methotrexate—bone cancer	0.000126	0.00121	CcSEcCtD
Indinavir—Myalgia—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Chest pain—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Arthralgia—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Agitation—Doxorubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Anxiety—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Skin disorder—Methotrexate—bone cancer	0.000125	0.0012	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000124	0.00119	CcSEcCtD
Indinavir—Hyperhidrosis—Methotrexate—bone cancer	0.000124	0.00119	CcSEcCtD
Indinavir—Discomfort—Epirubicin—bone cancer	0.000124	0.00119	CcSEcCtD
Indinavir—Malaise—Doxorubicin—bone cancer	0.000123	0.00118	CcSEcCtD
Indinavir—Dry mouth—Epirubicin—bone cancer	0.000123	0.00118	CcSEcCtD
Indinavir—Vertigo—Doxorubicin—bone cancer	0.000122	0.00117	CcSEcCtD
Indinavir—Anorexia—Methotrexate—bone cancer	0.000122	0.00117	CcSEcCtD
Indinavir—Syncope—Doxorubicin—bone cancer	0.000122	0.00117	CcSEcCtD
Indinavir—Palpitations—Doxorubicin—bone cancer	0.00012	0.00116	CcSEcCtD
Indinavir—Oedema—Epirubicin—bone cancer	0.00012	0.00115	CcSEcCtD
Indinavir—Anaphylactic shock—Epirubicin—bone cancer	0.00012	0.00115	CcSEcCtD
Indinavir—Loss of consciousness—Doxorubicin—bone cancer	0.00012	0.00115	CcSEcCtD
Indinavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000119	0.00334	CbGpPWpGaD
Indinavir—Cough—Doxorubicin—bone cancer	0.000119	0.00114	CcSEcCtD
Indinavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000118	0.00331	CbGpPWpGaD
Indinavir—Shock—Epirubicin—bone cancer	0.000118	0.00113	CcSEcCtD
Indinavir—Nervous system disorder—Epirubicin—bone cancer	0.000118	0.00113	CcSEcCtD
Indinavir—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000118	0.00329	CbGpPWpGaD
Indinavir—Thrombocytopenia—Epirubicin—bone cancer	0.000118	0.00113	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000117	0.00112	CcSEcCtD
Indinavir—Skin disorder—Epirubicin—bone cancer	0.000117	0.00112	CcSEcCtD
Indinavir—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000117	0.00326	CbGpPWpGaD
Indinavir—Hyperhidrosis—Epirubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Insomnia—Methotrexate—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Arthralgia—Doxorubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Chest pain—Doxorubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Myalgia—Doxorubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Anxiety—Doxorubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Indinavir—Paraesthesia—Methotrexate—bone cancer	0.000115	0.00111	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000115	0.00111	CcSEcCtD
Indinavir—Discomfort—Doxorubicin—bone cancer	0.000115	0.0011	CcSEcCtD
Indinavir—Anorexia—Epirubicin—bone cancer	0.000114	0.0011	CcSEcCtD
Indinavir—Dyspnoea—Methotrexate—bone cancer	0.000114	0.0011	CcSEcCtD
Indinavir—Somnolence—Methotrexate—bone cancer	0.000114	0.0011	CcSEcCtD
Indinavir—Dry mouth—Doxorubicin—bone cancer	0.000113	0.00109	CcSEcCtD
Indinavir—Dyspepsia—Methotrexate—bone cancer	0.000113	0.00108	CcSEcCtD
Indinavir—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000113	0.00316	CbGpPWpGaD
Indinavir—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000113	0.00316	CbGpPWpGaD
Indinavir—Decreased appetite—Methotrexate—bone cancer	0.000112	0.00107	CcSEcCtD
Indinavir—Oedema—Doxorubicin—bone cancer	0.000111	0.00107	CcSEcCtD
Indinavir—Anaphylactic shock—Doxorubicin—bone cancer	0.000111	0.00107	CcSEcCtD
Indinavir—Gastrointestinal disorder—Methotrexate—bone cancer	0.000111	0.00106	CcSEcCtD
Indinavir—Fatigue—Methotrexate—bone cancer	0.000111	0.00106	CcSEcCtD
Indinavir—Pain—Methotrexate—bone cancer	0.00011	0.00105	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000109	0.00105	CcSEcCtD
Indinavir—Shock—Doxorubicin—bone cancer	0.000109	0.00105	CcSEcCtD
Indinavir—Nervous system disorder—Doxorubicin—bone cancer	0.000109	0.00105	CcSEcCtD
Indinavir—Thrombocytopenia—Doxorubicin—bone cancer	0.000109	0.00104	CcSEcCtD
Indinavir—Insomnia—Epirubicin—bone cancer	0.000109	0.00104	CcSEcCtD
Indinavir—Skin disorder—Doxorubicin—bone cancer	0.000108	0.00104	CcSEcCtD
Indinavir—Paraesthesia—Epirubicin—bone cancer	0.000108	0.00104	CcSEcCtD
Indinavir—Hyperhidrosis—Doxorubicin—bone cancer	0.000107	0.00103	CcSEcCtD
Indinavir—Dyspnoea—Epirubicin—bone cancer	0.000107	0.00103	CcSEcCtD
Indinavir—Somnolence—Epirubicin—bone cancer	0.000107	0.00102	CcSEcCtD
Indinavir—Anorexia—Doxorubicin—bone cancer	0.000106	0.00102	CcSEcCtD
Indinavir—Feeling abnormal—Methotrexate—bone cancer	0.000106	0.00102	CcSEcCtD
Indinavir—Dyspepsia—Epirubicin—bone cancer	0.000106	0.00101	CcSEcCtD
Indinavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000105	0.00294	CbGpPWpGaD
Indinavir—Gastrointestinal pain—Methotrexate—bone cancer	0.000105	0.00101	CcSEcCtD
Indinavir—Decreased appetite—Epirubicin—bone cancer	0.000104	0.001	CcSEcCtD
Indinavir—Gastrointestinal disorder—Epirubicin—bone cancer	0.000104	0.000995	CcSEcCtD
Indinavir—Fatigue—Epirubicin—bone cancer	0.000104	0.000994	CcSEcCtD
Indinavir—Constipation—Epirubicin—bone cancer	0.000103	0.000986	CcSEcCtD
Indinavir—Pain—Epirubicin—bone cancer	0.000103	0.000986	CcSEcCtD
Indinavir—Urticaria—Methotrexate—bone cancer	0.000102	0.000979	CcSEcCtD
Indinavir—Body temperature increased—Methotrexate—bone cancer	0.000101	0.000974	CcSEcCtD
Indinavir—Abdominal pain—Methotrexate—bone cancer	0.000101	0.000974	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000101	0.000972	CcSEcCtD
Indinavir—Insomnia—Doxorubicin—bone cancer	0.000101	0.000965	CcSEcCtD
Indinavir—CYP3A7—Biological oxidations—CYP3A4—bone cancer	9.99e-05	0.00279	CbGpPWpGaD
Indinavir—Paraesthesia—Doxorubicin—bone cancer	9.98e-05	0.000958	CcSEcCtD
Indinavir—Dyspnoea—Doxorubicin—bone cancer	9.91e-05	0.000951	CcSEcCtD
Indinavir—Feeling abnormal—Epirubicin—bone cancer	9.9e-05	0.00095	CcSEcCtD
Indinavir—Somnolence—Doxorubicin—bone cancer	9.88e-05	0.000948	CcSEcCtD
Indinavir—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	9.85e-05	0.00276	CbGpPWpGaD
Indinavir—Gastrointestinal pain—Epirubicin—bone cancer	9.82e-05	0.000943	CcSEcCtD
Indinavir—Dyspepsia—Doxorubicin—bone cancer	9.78e-05	0.000939	CcSEcCtD
Indinavir—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.75e-05	0.00273	CbGpPWpGaD
Indinavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.66e-05	0.0027	CbGpPWpGaD
Indinavir—Decreased appetite—Doxorubicin—bone cancer	9.66e-05	0.000927	CcSEcCtD
Indinavir—Gastrointestinal disorder—Doxorubicin—bone cancer	9.59e-05	0.000921	CcSEcCtD
Indinavir—Fatigue—Doxorubicin—bone cancer	9.58e-05	0.00092	CcSEcCtD
Indinavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.58e-05	0.00268	CbGpPWpGaD
Indinavir—Urticaria—Epirubicin—bone cancer	9.54e-05	0.000916	CcSEcCtD
Indinavir—Pain—Doxorubicin—bone cancer	9.5e-05	0.000912	CcSEcCtD
Indinavir—Constipation—Doxorubicin—bone cancer	9.5e-05	0.000912	CcSEcCtD
Indinavir—Body temperature increased—Epirubicin—bone cancer	9.49e-05	0.000911	CcSEcCtD
Indinavir—Abdominal pain—Epirubicin—bone cancer	9.49e-05	0.000911	CcSEcCtD
Indinavir—Hypersensitivity—Methotrexate—bone cancer	9.45e-05	0.000908	CcSEcCtD
Indinavir—Asthenia—Methotrexate—bone cancer	9.21e-05	0.000884	CcSEcCtD
Indinavir—Feeling abnormal—Doxorubicin—bone cancer	9.16e-05	0.000879	CcSEcCtD
Indinavir—Gastrointestinal pain—Doxorubicin—bone cancer	9.09e-05	0.000872	CcSEcCtD
Indinavir—Pruritus—Methotrexate—bone cancer	9.08e-05	0.000872	CcSEcCtD
Indinavir—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.88e-05	0.00249	CbGpPWpGaD
Indinavir—Hypersensitivity—Epirubicin—bone cancer	8.85e-05	0.000849	CcSEcCtD
Indinavir—Urticaria—Doxorubicin—bone cancer	8.83e-05	0.000847	CcSEcCtD
Indinavir—Body temperature increased—Doxorubicin—bone cancer	8.78e-05	0.000843	CcSEcCtD
Indinavir—Abdominal pain—Doxorubicin—bone cancer	8.78e-05	0.000843	CcSEcCtD
Indinavir—Diarrhoea—Methotrexate—bone cancer	8.78e-05	0.000843	CcSEcCtD
Indinavir—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.78e-05	0.00246	CbGpPWpGaD
Indinavir—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	8.75e-05	0.00245	CbGpPWpGaD
Indinavir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	8.68e-05	0.00243	CbGpPWpGaD
Indinavir—Asthenia—Epirubicin—bone cancer	8.62e-05	0.000827	CcSEcCtD
Indinavir—CYP3A7—Biological oxidations—GSTP1—bone cancer	8.54e-05	0.00239	CbGpPWpGaD
Indinavir—Pruritus—Epirubicin—bone cancer	8.5e-05	0.000816	CcSEcCtD
Indinavir—Dizziness—Methotrexate—bone cancer	8.49e-05	0.000815	CcSEcCtD
Indinavir—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	8.42e-05	0.00236	CbGpPWpGaD
Indinavir—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.42e-05	0.00236	CbGpPWpGaD
Indinavir—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.34e-05	0.00233	CbGpPWpGaD
Indinavir—Diarrhoea—Epirubicin—bone cancer	8.22e-05	0.000789	CcSEcCtD
Indinavir—Hypersensitivity—Doxorubicin—bone cancer	8.19e-05	0.000786	CcSEcCtD
Indinavir—Vomiting—Methotrexate—bone cancer	8.16e-05	0.000783	CcSEcCtD
Indinavir—Rash—Methotrexate—bone cancer	8.09e-05	0.000777	CcSEcCtD
Indinavir—Dermatitis—Methotrexate—bone cancer	8.08e-05	0.000776	CcSEcCtD
Indinavir—Headache—Methotrexate—bone cancer	8.04e-05	0.000772	CcSEcCtD
Indinavir—Asthenia—Doxorubicin—bone cancer	7.97e-05	0.000765	CcSEcCtD
Indinavir—Dizziness—Epirubicin—bone cancer	7.94e-05	0.000762	CcSEcCtD
Indinavir—Pruritus—Doxorubicin—bone cancer	7.86e-05	0.000755	CcSEcCtD
Indinavir—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.67e-05	0.00215	CbGpPWpGaD
Indinavir—Vomiting—Epirubicin—bone cancer	7.64e-05	0.000733	CcSEcCtD
Indinavir—SLCO1A2—Metabolism—NDUFA12—bone cancer	7.63e-05	0.00213	CbGpPWpGaD
Indinavir—Nausea—Methotrexate—bone cancer	7.62e-05	0.000732	CcSEcCtD
Indinavir—Diarrhoea—Doxorubicin—bone cancer	7.6e-05	0.00073	CcSEcCtD
Indinavir—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.58e-05	0.00212	CbGpPWpGaD
Indinavir—Rash—Epirubicin—bone cancer	7.57e-05	0.000727	CcSEcCtD
Indinavir—Dermatitis—Epirubicin—bone cancer	7.57e-05	0.000726	CcSEcCtD
Indinavir—Headache—Epirubicin—bone cancer	7.52e-05	0.000722	CcSEcCtD
Indinavir—Dizziness—Doxorubicin—bone cancer	7.35e-05	0.000705	CcSEcCtD
Indinavir—CYP3A5—Biological oxidations—CYP3A4—bone cancer	7.22e-05	0.00202	CbGpPWpGaD
Indinavir—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.2e-05	0.00201	CbGpPWpGaD
Indinavir—Nausea—Epirubicin—bone cancer	7.13e-05	0.000685	CcSEcCtD
Indinavir—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.12e-05	0.00199	CbGpPWpGaD
Indinavir—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	7.12e-05	0.00199	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.1e-05	0.00199	CbGpPWpGaD
Indinavir—Vomiting—Doxorubicin—bone cancer	7.07e-05	0.000678	CcSEcCtD
Indinavir—Rash—Doxorubicin—bone cancer	7.01e-05	0.000673	CcSEcCtD
Indinavir—Dermatitis—Doxorubicin—bone cancer	7e-05	0.000672	CcSEcCtD
Indinavir—Headache—Doxorubicin—bone cancer	6.96e-05	0.000668	CcSEcCtD
Indinavir—ABCC1—Metabolism—NDUFA12—bone cancer	6.86e-05	0.00192	CbGpPWpGaD
Indinavir—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	6.64e-05	0.00186	CbGpPWpGaD
Indinavir—Nausea—Doxorubicin—bone cancer	6.6e-05	0.000634	CcSEcCtD
Indinavir—SLCO1B1—Metabolism—NDUFA12—bone cancer	6.52e-05	0.00182	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—NT5C3A—bone cancer	6.32e-05	0.00177	CbGpPWpGaD
Indinavir—CYP3A5—Biological oxidations—GSTP1—bone cancer	6.17e-05	0.00173	CbGpPWpGaD
Indinavir—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.15e-05	0.00172	CbGpPWpGaD
Indinavir—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	6.09e-05	0.0017	CbGpPWpGaD
Indinavir—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.06e-05	0.0017	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.04e-05	0.00169	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—NDUFA12—bone cancer	5.99e-05	0.00167	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—NT5C3A—bone cancer	5.69e-05	0.00159	CbGpPWpGaD
Indinavir—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.58e-05	0.00156	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—NDUFA12—bone cancer	5.57e-05	0.00156	CbGpPWpGaD
Indinavir—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.5e-05	0.00154	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.5e-05	0.00154	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—NT5C3A—bone cancer	5.4e-05	0.00151	CbGpPWpGaD
Indinavir—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.13e-05	0.00144	CbGpPWpGaD
Indinavir—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.09e-05	0.00142	CbGpPWpGaD
Indinavir—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.06e-05	0.00142	CbGpPWpGaD
Indinavir—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.02e-05	0.0014	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.01e-05	0.0014	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—NT5C3A—bone cancer	4.96e-05	0.00139	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.94e-05	0.00138	CbGpPWpGaD
Indinavir—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.77e-05	0.00134	CbGpPWpGaD
Indinavir—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.71e-05	0.00132	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.68e-05	0.00131	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—NT5C3A—bone cancer	4.62e-05	0.00129	CbGpPWpGaD
Indinavir—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	4.52e-05	0.00126	CbGpPWpGaD
Indinavir—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.43e-05	0.00124	CbGpPWpGaD
Indinavir—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.39e-05	0.00123	CbGpPWpGaD
Indinavir—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.35e-05	0.00122	CbGpPWpGaD
Indinavir—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.33e-05	0.00121	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—NDUFA12—bone cancer	4.33e-05	0.00121	CbGpPWpGaD
Indinavir—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.29e-05	0.0012	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.19e-05	0.00117	CbGpPWpGaD
Indinavir—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.18e-05	0.00117	CbGpPWpGaD
Indinavir—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	3.79e-05	0.00106	CbGpPWpGaD
Indinavir—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.6e-05	0.00101	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—NT5C3A—bone cancer	3.59e-05	0.001	CbGpPWpGaD
Indinavir—SLC22A1—Neuronal System—BRAF—bone cancer	3.46e-05	0.000969	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—NDUFA12—bone cancer	3.34e-05	0.000936	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—NDUFA12—bone cancer	3.26e-05	0.000914	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.11e-05	0.000869	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—NDUFA12—bone cancer	3.08e-05	0.000861	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—NDUFA12—bone cancer	3.05e-05	0.000853	CbGpPWpGaD
Indinavir—ABCC1—Disease—ENO2—bone cancer	2.97e-05	0.000832	CbGpPWpGaD
Indinavir—SLC22A1—Neuronal System—MDM2—bone cancer	2.9e-05	0.000812	CbGpPWpGaD
Indinavir—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.87e-05	0.000803	CbGpPWpGaD
Indinavir—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.83e-05	0.000792	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—NT5C3A—bone cancer	2.77e-05	0.000776	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—ENO2—bone cancer	2.77e-05	0.000775	CbGpPWpGaD
Indinavir—ABCC1—Disease—DHFR—bone cancer	2.76e-05	0.000772	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—NT5C3A—bone cancer	2.71e-05	0.000757	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—DHFR—bone cancer	2.57e-05	0.000719	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—NT5C3A—bone cancer	2.55e-05	0.000713	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—NT5C3A—bone cancer	2.53e-05	0.000707	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—ENO2—bone cancer	2.49e-05	0.000697	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—GNA11—bone cancer	2.4e-05	0.000672	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—ENO2—bone cancer	2.37e-05	0.000662	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—DHFR—bone cancer	2.31e-05	0.000647	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.3e-05	0.000644	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.22e-05	0.000621	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—DHFR—bone cancer	2.2e-05	0.000614	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.18e-05	0.000609	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—ENO2—bone cancer	2.17e-05	0.000608	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.16e-05	0.000606	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—GNA11—bone cancer	2.16e-05	0.000604	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—GNA11—bone cancer	2.05e-05	0.000574	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—ENO2—bone cancer	2.02e-05	0.000566	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—DHFR—bone cancer	2.02e-05	0.000564	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—NDUFA12—bone cancer	2.01e-05	0.000563	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2e-05	0.00056	CbGpPWpGaD
Indinavir—ABCC1—Disease—TGFBR2—bone cancer	2e-05	0.000559	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—CYP3A4—bone cancer	1.96e-05	0.000548	CbGpPWpGaD
Indinavir—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.95e-05	0.000545	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—GNA11—bone cancer	1.88e-05	0.000527	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—DHFR—bone cancer	1.88e-05	0.000525	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—GSTP1—bone cancer	1.86e-05	0.000521	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.86e-05	0.000521	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.85e-05	0.000518	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—GNA11—bone cancer	1.75e-05	0.00049	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—CYP3A4—bone cancer	1.71e-05	0.000478	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—GSTP1—bone cancer	1.67e-05	0.000469	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—NT5C3A—bone cancer	1.67e-05	0.000466	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—GSTP1—bone cancer	1.59e-05	0.000445	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—CYP3A4—bone cancer	1.59e-05	0.000445	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.57e-05	0.00044	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—ENO2—bone cancer	1.57e-05	0.000439	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—GSTP1—bone cancer	1.46e-05	0.000409	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—DHFR—bone cancer	1.46e-05	0.000408	CbGpPWpGaD
Indinavir—ABCC1—Disease—KIT—bone cancer	1.36e-05	0.000382	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—GNA11—bone cancer	1.36e-05	0.000381	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—GSTP1—bone cancer	1.36e-05	0.00038	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.32e-05	0.00037	CbGpPWpGaD
Indinavir—ABCC1—Disease—BRAF—bone cancer	1.28e-05	0.000359	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—CYP3A4—bone cancer	1.23e-05	0.000345	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—ENO2—bone cancer	1.21e-05	0.00034	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—ENO2—bone cancer	1.18e-05	0.000332	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—DHFR—bone cancer	1.13e-05	0.000315	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—ENO2—bone cancer	1.12e-05	0.000312	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—ENO2—bone cancer	1.11e-05	0.00031	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—DHFR—bone cancer	1.1e-05	0.000308	CbGpPWpGaD
Indinavir—ABCC1—Disease—MDM2—bone cancer	1.07e-05	0.000301	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—GSTP1—bone cancer	1.06e-05	0.000295	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—GNA11—bone cancer	1.05e-05	0.000295	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—DHFR—bone cancer	1.04e-05	0.00029	CbGpPWpGaD
Indinavir—ABCC1—Disease—PTGS2—bone cancer	1.04e-05	0.00029	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—GNA11—bone cancer	1.03e-05	0.000287	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—DHFR—bone cancer	1.03e-05	0.000287	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—GNA11—bone cancer	9.68e-06	0.000271	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—PTGS2—bone cancer	9.64e-06	0.00027	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—GNA11—bone cancer	9.6e-06	0.000269	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—CYP3A4—bone cancer	9.54e-06	0.000267	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.49e-06	0.000266	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—CYP3A4—bone cancer	9.31e-06	0.000261	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—CYP3A4—bone cancer	8.78e-06	0.000246	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—CYP3A4—bone cancer	8.7e-06	0.000243	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—PTGS2—bone cancer	8.68e-06	0.000243	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.66e-06	0.000242	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—PTGS2—bone cancer	8.24e-06	0.000231	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—GSTP1—bone cancer	8.16e-06	0.000228	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—GSTP1—bone cancer	7.97e-06	0.000223	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—PTGS2—bone cancer	7.57e-06	0.000212	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—GSTP1—bone cancer	7.51e-06	0.00021	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—GSTP1—bone cancer	7.44e-06	0.000208	CbGpPWpGaD
Indinavir—ABCC1—Disease—EGFR—bone cancer	7.34e-06	0.000205	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—ENO2—bone cancer	7.3e-06	0.000204	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—PTGS2—bone cancer	7.04e-06	0.000197	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—DHFR—bone cancer	6.77e-06	0.00019	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—GNA11—bone cancer	6.33e-06	0.000177	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—PTGS2—bone cancer	5.47e-06	0.000153	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—GSTP1—bone cancer	4.91e-06	0.000137	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—PTGS2—bone cancer	4.23e-06	0.000118	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—PTGS2—bone cancer	4.13e-06	0.000115	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—PTGS2—bone cancer	3.89e-06	0.000109	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—PTGS2—bone cancer	3.86e-06	0.000108	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—PTGS2—bone cancer	2.54e-06	7.12e-05	CbGpPWpGaD
